Lamivudine Teva Pharma (Lamivudine)

Lamivudine is a nucleoside analog that is converted inside cells to its active triphosphate form. This active metabolite competes with natural nucleosides for incorporation into viral DNA by reverse transcriptase, causing premature chain termination and halting viral replication.

The prescribed dose of lamivudine is determined by the treating physician based on the patient’s age, weight, renal function, and the specific indication. Dosage regimens may differ for HIV versus hepatitis B treatment.

Lamivudine is classified as pregnancy category B, indicating that animal studies have not shown risk to the fetus and there are no well‑controlled studies in pregnant women. It may be used during pregnancy when the potential benefit justifies the potential risk. Breastfeeding decisions should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lamivudine belongs to the nucleoside reverse transcriptase inhibitor (NRTI) class, offering a favorable safety profile and convenient once‑daily dosing. Compared with older NRTIs such as didanosine or stavudine, lamivudine has lower rates of mitochondrial toxicity and peripheral neuropathy, making it a common component of modern combination regimens.

Lamivudine tablets should be stored at temperatures below 25 °C, in their original packaging, and protected from moisture and direct sunlight. Do not store in a humid environment or expose to excessive heat.

Lamivudine is taken orally, usually with or without food, as a whole tablet. The exact timing and whether it should be taken with meals are determined by the prescribing clinician.

Serious risks include lactic acidosis, severe hepatotoxicity, pancreatitis, and rare hypersensitivity reactions such as Stevens‑Johnson syndrome. Patients should be educated to report unexplained abdominal pain, rapid weight loss, persistent nausea, or skin rashes promptly.

Lamivudine is contraindicated in patients with known hypersensitivity to the drug or any of its components. Caution is also advised for individuals with severe renal or hepatic impairment, and it should be avoided in combination with drugs that have overlapping toxicities unless closely monitored.